BMS to Deploy Claude Agentic AI Across 30,000 Employees

Bristol Myers Squibb (BMS) has signed a strategic agreement with Anthropic to deploy Claude across its research, clinical development, manufacturing, commercial, and corporate functions.

The collaboration signals an evolution in how BMS deploys AI, moving beyond conversational tools that have defined the first wave of enterprise adoption, toward agentic capabilities built into the day-to-day workflows and systems that underpin its science and global operations.

BMS says it will deploy Claude broadly across the company, “empowering more than 30,000 employees with advanced reasoning and agentic capabilities.”

“The companies that lead the next decade of biopharma will be the ones that learn to operate fundamentally differently with AI, and BMS intends to be one of them.”

Greg Meyers, EVP and Chief Digital & Technology Officer, Bristol Myers Squibb

Where Claude Will be Deployed

The deployment focuses on three priorities where BMS expects the highest near-term impact:

• Accelerating engineering with Claude Code: BMS’ engineering and data science teams will leverage Claude Code to speed software and AI development.
• Embedding agents into the workflows that move drugs forward: BMS will evaluate the potential for Claude to serve as the agentic layer within priority workflows where AI is already driving impact across the value chain, including research, drug development, manufacturing & quality, and commercial & medical affairs.
• Connecting Claude to the institutional knowledge that lives across BMS: Through secure integrations with the systems and repositories where BMS’ scientific, clinical, regulatory, and commercial expertise resides, Claude’s agentic capabilities will help connect and activate that knowledge where and when it is most needed, with full enterprise governance and audit controls in place.

The collaboration builds on more than three years of AI investment at BMS. Most recently, in January, the company joined forces with Immunai, an AI biotech company specializing in mapping the human immune system, to advance clinical development.

“For more than 160 years, BMS has pushed the boundaries of science to transform patients’ lives, and artificial intelligence is the single most powerful opportunity we have to accelerate that mission today,” said Greg Meyers, EVP and Chief Digital & Technology Officer, Bristol Myers Squibb. “Anthropic’s Claude gives us the agentic capabilities, pace of innovation, and security necessary to connect our systems and put that collective knowledge in the hands of every BMS employee to accelerate innovation for patients. The companies that lead the next decade of biopharma will be the ones that learn to operate fundamentally differently with AI, and BMS intends to be one of them.”

“By giving employees access to Claude’s agentic capabilities — connected to thousands of data sources across the company — BMS is creating a single intelligence layer that can generate a clinical study report from underlying trial data, surface the right scientific context from decades of internal research, or trace the root cause of a manufacturing deviation in real time,” said Eric Kauderer-Abrams, Head of Life Sciences, Anthropic. “In a regulated global enterprise, that means medicines reach patients faster — with BMS’ scientific depth and operational rigor accelerated by Claude agents at every step.”